Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2 seropositive persons during early HIV-1 infection

H. Nina Kim, Jing Wang, James Hughes, Robert Coombs, Jorge Sanchez, Stewart Reid, Sinead Delany-Moretlwe, Frances Cowan, Jonathan Fuchs, Susan H. Eshleman, Leila Khaki, Moira A. McMahon, Robert F. Siliciano, Anna Wald, Connie Celum

Research output: Contribution to journalArticlepeer-review

Abstract

We evaluated whether acyclovir suppression during human immunodeficiency virus type 1 (HIV-1) acquisition reduces HIV-1 set point, increases CD4 cell counts, and selects reverse- transcriptase mutations among 76 HIV-1 seroconverters identified in a placebo-controlled trial of twice-daily acyclovir (400 mg) for the prevention of HIV acquisition in herpes simplex virus type 2 (HSV-2)-seropositive persons(HIV Prevention Trials Network study 039). We found no significant difference in plasma HIV-1 RNA levels (Pp.30) or CD4 cell counts (Pp.85) between the acyclovir and placebo recipients. V75I and other mutations in HIV-1 reverse transcriptase reported from in vitro acyclovir studies were not observed. In conclusion, acyclovir suppression during HIV-1 seroconversion and the subsequent 6 months does not affect HIV-1 set point.

Original languageEnglish (US)
Pages (from-to)734-738
Number of pages5
JournalJournal of Infectious Diseases
Volume202
Issue number5
DOIs
StatePublished - Sep 1 2010

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2 seropositive persons during early HIV-1 infection'. Together they form a unique fingerprint.

Cite this